Phase 1b Single Dose Clinical Trial of a Novel Long-Acting Bispecific Antibody in People With HIV to Inform Development for HIV Pre- and Post-Exposure Prophylaxis

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 13 Jan 2025

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Ibalizumab (Primary) ; Ibalizumab (Primary) ; TMB-380 (Primary) ; Antiretrovirals
Indications HIV infections
Focus Adverse reactions; Pharmacodynamics; Therapeutic Use

10 Jan 2025 Planned End Date changed from 1 Feb 2025 to 1 Feb 2026.
10 Jan 2025 Planned primary completion date changed from 1 Dec 2024 to 1 May 2025.
12 Dec 2023 Status changed from not yet recruiting to recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com